ecancer

ecancer.org

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

 

EHA 2022
04:46

ecancer

Phase II Expansion Results: Glofitamab Induces Durable Complete Remissions in Patients With R/R DLBCL and ≥2 Prior Therapies

FEATURING Michael Dickinson
  • 21 views
  • June 28, 2022
03:35

ecancer

EHA 2022: Quizartinib Improves OS in Adults With FLT3-ITD+ AML

FEATURING Harry P. Erba
  • 32 views
  • June 25, 2022
06:01

ecancer

EHA 2022: Ponatinib & Blinatumomab for Patients With Ph+ ALL

FEATURING Nicholas Short
  • 149 views
  • June 24, 2022
  • 2
07:31

ecancer

EHA 2022 on CLIMB THAL-111 and CLIMB SCD-121 Studies: Single-Dose ctx001 Shows Promising Efficacy & Safety for TDT and Severe SCD

FEATURING Franco Locatelli
  • 22 views
  • June 23, 2022
03:54

ecancer

EHA 2022 on a Bispecific Antibody Talquetamab in R/R MM: Safety & Efficacy Results From the MonumenTAL-1 Trial

FEATURING Monique Minnema
  • 25 views
  • June 21, 2022
05:24

ecancer

EHA 2022 CARTBCMA-HCB-01 Study Updates: A Novel CAR T-Cell Therapy Targeting BCMA Is Highly Effective for R/R MM

FEATURING Carlos Fernandez De Larrea
  • 105 views
  • June 21, 2022
03:44

ecancer

EHA 2022 on R-CODOX-M/R-IVAC vs. Dose-Adjusted EPOCH-R in Newly Diagnosed High-Risk Burkitt Lymphoma

FEATURING Martine Chamuleau
  • 25 views
  • June 21, 2022
04:51

ecancer

EHA 2022 on Targeted Therapy Combinations With Venetoclax Superior to Chemoimmunotherapy in Frontline CLL: Randomised Phase III GAIA/CLL13 Trial

FEATURING Barbara Eichhorst
  • 97 views
  • June 21, 2022
04:29

ecancer

EHA 2022 Time-Limited Venetoclax-Obinutuzumab +/- Ibrutinib Surpasses Chemoimmunotherapy in Frontline CLL: Phase III GAIA/CLL13 Trial Updates

FEATURING Barbara Eichhorst
  • 244 views
  • June 21, 2022
03:35

ecancer

EHA 2022 on the Efficacy & Safety of ARI0002H, a BCMA-Directed CAR T-Cell Therapy With Fractionated Initial Therapy and Booster Dose in R/R MM

FEATURING Carlos Fernandez De Larrea
  • 8 views
  • June 21, 2022
04:29

ecancer

EHA 2022 on a Phase III GMMG-HD7 Trial: Isa-RVd as Induction Therapy for NDMM Patients

FEATURING Elias Mai
  • 100 views
  • June 21, 2022
  • 1
02:19

ecancer

Lecture Summary - EHA 2022: Lenalidomide, Bortezomib, and Dexamethasone ASCT to Progress for NDMM

FEATURING Paul Richardson
  • 4 views
  • June 17, 2022